ALMDT.PA Mediantechn

Healthcare Health Care Technology Euronext Paris
3.53 EUR
Close of Nov 8, 2026
2.75 7.27
Market cap
EUR 173M
P/E
-
P/B
252.66x
ROE
-
Dividend yield
-
Fundamental score
2.0/5

Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.

Is ALMDT.PA undervalued?

Graham number

The Graham number of Mediantechn cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Mediantechn fundamental analysis

4 of 11 checks passed

ROE 2/2

ROE surpassing expectations (1747.1%) highlights strong profitability and efficient use of shareholders' equity, making it an appealing investment prospect.

ROA 0/2

The stock's ROA (-59.82%) suggests that it's struggling to generate profits from its assets, making it a risky choice for investment.

PBV 2/2

The stock's low PBV ratio (-9.3x) suggests it's undervalued, making it an attractive opportunity for investors.

DER 2/2

The stock has a low debt to equity ratio (-250%), which means it has a small amount of debt compared to the ownership it holds

Revenue Growth 2/2

Over the past five years, this company's revenue has consistently increased, demonstrating a robust financial performance that makes it an appealing opportunity.

Net Profit Growth 0/2

Throughout the last five years, this company's net profit has remained unchanged, indicating a lack of growth and making it a less favorable investment option.

Assets Growth 0/2

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

Graham Number 0/1

The company's Graham number suggests that its stock price is overestimated, implying that it may not be a promising investment opportunity.

Dividend Growth 0/2

The company's dividend growth has remained unchanged for three years, signaling a lack of positive momentum and making it a less favorable investment choice.

Dividend 0/2

The company's decision to withhold dividends for three years raises questions about its ability to generate consistent returns.

Buffet Intrinsic Value 0/1

The company's stock shows signs of being overvalued (-5) according to Warren Buffett's formula, indicating a potential downside as its market price exceeds its estimated intrinsic value.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Mediantechn stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Mediantechn

Median Technologies SA develops and markets software solutions and services for the use of medical images for the diagnosis and monitoring of patients with cancer in Europe, North America, and Asia. The company offers iCRO, an imaging service for oncology clinical trials; and eyonis, an end-to-end CADe/CADx software as medical devices. The company was founded in 2002 and is based in Valbonne, France.

Full company profile